Dynamics of the Immune Response in Hospitalized SARS-CoV-2-infected Cancer Patients.

Autor: Aoki MN; Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Brazil., Nardin JM; Erasto Gaertner Hospital, Curitiba, Brazil., Huergo LF; Setor Litoral, Federal University of Paraná (UFPR), Matinhos, Brazil., Blanes L; Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Brazil., Morales HMP; Erasto Gaertner Hospital, Curitiba, Brazil., Fornazari B; Erasto Gaertner Hospital, Curitiba, Brazil., Conzentino MS; Setor Litoral, Federal University of Paraná (UFPR), Matinhos, Brazil., Migliorini MEA; Erasto Gaertner Hospital, Curitiba, Brazil., Zanette DL; Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Brazil.
Jazyk: angličtina
Zdroj: Cancer investigation [Cancer Invest] 2022 Oct; Vol. 40 (9), pp. 750-759. Date of Electronic Publication: 2022 Aug 21.
DOI: 10.1080/07357907.2022.2112693
Abstrakt: Seroconversion rates were compared between oncological and nononcological patients infected with SARS-CoV-2 during a 14-day hospitalization time. All COVID-19 non-oncological and solid malignancies patients reached 100% seroconversion at day 14, while less than half of the hematological patients were seroconverted at the same time point. Despite the limited number and variability of the patient's cohort, we conclude that there is a delayed seroconversion in the hematological malignancies group, which may be linked to changes in the hematological parameters, immune suppression and/or oncological treatments that are typically associated with these patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje